Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
Umfang
1 Online-Ressource.
Sprache
Englisch

Erschienen in
Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population ; volume:40 ; number:3 ; day:19 ; month:1 ; year:2023 ; pages:1224-1241 ; date:3.2023
Advances in therapy ; 40, Heft 3 (19.1.2023), 1224-1241, 3.2023

Urheber
Berger, Jeffrey S.
Ashton, Veronica
Laliberté, François
Germain, Guillaume
Bookhart, Brahim
Lejeune, Dominique
Boudreau, Julien
Lefebvre, Patrick
Weir, Matthew R.
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1007/s12325-022-02422-9
URN
urn:nbn:de:101:1-2408192208597.446915036656
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:54 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Berger, Jeffrey S.
  • Ashton, Veronica
  • Laliberté, François
  • Germain, Guillaume
  • Bookhart, Brahim
  • Lejeune, Dominique
  • Boudreau, Julien
  • Lefebvre, Patrick
  • Weir, Matthew R.
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation

Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users

Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users

Implementing hospital guidelines improves warfarin use in non-valvular atrial fibrillation: a before-after study

Implementing hospital guidelines improves warfarin use in non-valvular atrial fibrillation: a before-after study

Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users

Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users

Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy

Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy

Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation

Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation

Effectiveness and Safety of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Concomitant Obstructive Sleep Apnea

Effectiveness and Safety of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Concomitant Obstructive Sleep Apnea

Psychiatric symptoms in patients with non-valvular atrial fibrillation

Psychiatric symptoms in patients with non-valvular atrial fibrillation

Comparing the Clinical Outcomes Observed with Rivaroxaban Versus Warfarin for the Management of Obese Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis

Comparing the Clinical Outcomes Observed with Rivaroxaban Versus Warfarin for the Management of Obese Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis

Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation

Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation

Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin

Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin

Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes

Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes

Verbundene Objekte